Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05161936 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels
A Phase 2 study, sponsored by Alnylam Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT05161936 is a Phase 2 study that was terminated before completion, run by Alnylam Pharmaceuticals. The registered enrollment target is 2 participants.
The verdict
NCT05161936, a Phase 2 study, was terminated before completion, sponsored by Alnylam Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the effect of lumasiran on the percent change in urinary oxalate excretion in patients with recurrent calcium oxalate kidney stone disease.
Interventions
- DRUG Placebo
- DRUG Lumasiran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-01-27 |
| Est. Completion | 2022-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05161936
The ClinicalTrials.gov registry entry for NCT05161936 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05161936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05161936 about?
NCT05161936 is a clinical study titled "A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels". The primary purpose of this study is to evaluate the effect of lumasiran on the percent change in urinary oxalate excretion in patients with recurrent calcium oxalate kidney stone disease.
What is the current status of trial NCT05161936?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2022-01-27. Estimated completion is 2022-11-01.
What interventions are being tested in trial NCT05161936?
The interventions under investigation include: Placebo (DRUG), Lumasiran (DRUG).
Who is sponsoring clinical trial NCT05161936?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.